Novartis wraps first phase of Alcon buyout

Novartis completed the first stage of its $38 billion takeover of the U.S. eye care company Alcon, paying Nestle $10.4 billion in cash for a 25 percent stake in the company, some $200 million less than the originally announced price. Novartis retains exclusive rights to buy Nestle's remaining 52 percent share. Report

Suggested Articles

Eli Lilly and Incyte are investing heavily in JAK inhibitor Olumiant's chances in atopic dermatitis, but does it stand a chance against Dupixent?

Krystal Biotech has started on a new manufacturing facility for eventual commercial supply of gene therapies in its pipeline.

Chinese authorities have recommended trying AbbVie's HIV combo therapy Kaletra to treat the new coronavirus ravaging the country—and spreading fast.